Esperion Therapeutics, Inc.
ESPR
$2.18
-$0.01-0.46%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 26.76% | -5.96% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 26.76% | -5.96% | |||
| Cost of Revenue | -18.85% | 20.45% | |||
| Gross Profit | 122.99% | -35.70% | |||
| SG&A Expenses | -8.11% | 16.44% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.55% | 18.44% | |||
| Operating Income | 132.11% | -399.91% | |||
| Income Before Tax | 68.55% | -89.77% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 68.55% | -89.77% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 68.55% | -89.77% | |||
| EBIT | 132.11% | -399.91% | |||
| EBITDA | 132.27% | -402.39% | |||
| EPS Basic | 68.78% | -89.27% | |||
| Normalized Basic EPS | 68.74% | -105.25% | |||
| EPS Diluted | 69.33% | -92.66% | |||
| Normalized Diluted EPS | 68.74% | -105.25% | |||
| Average Basic Shares Outstanding | 0.72% | 0.29% | |||
| Average Diluted Shares Outstanding | 0.72% | 0.29% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||